$0.28
1.27% yesterday
NYSE, Aug 12, 10:11 pm CET
ISIN
US14216R1014
Symbol
CARM

Carisma Therapeutics Stock price

$0.28
-0.17 38.11% 1M
-0.18 39.36% 6M
-0.14 33.38% YTD
-0.66 70.22% 1Y
-0.96 77.40% 3Y
-1.52 84.49% 5Y
-6.93 96.13% 10Y
-18.85 98.54% 20Y
NYSE, Closing price Tue, Aug 12 2025
+0.00 1.27%
ISIN
US14216R1014
Symbol
CARM
Industry

Key metrics

Basic
Market capitalization
$11.5m
Enterprise Value
$4.4m
Net debt
positive
Cash
$7.7m
Shares outstanding
41.8m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
0.6 | 0.6
EV/Sales
0.2 | 0.2
EV/FCF
negative
P/B
negative
Dividends
DPS
$0.00
Yield 1Y | 5Y
0.0% | 0.0%
Growth 1Y | 5Y
- | -
Payout 1Y | 3Y
0.0% | -85.4%
Increased
0 Years
Financials (TTM | estimate)
Revenue
$20.0m | $17.9m
EBITDA
$-49.7m | -
EBIT
$-52.0m | $-17.3m
Net Income
$-50.8m | $-27.5m
Free Cash Flow
$-47.7m
Growth (TTM | estimate)
Revenue
32.4% | -9.1%
EBITDA
39.0% | -
EBIT
39.0% | 72.1%
Net Income
37.5% | 54.6%
Free Cash Flow
39.7%
Margin (TTM | estimate)
Gross
-
EBITDA
-248.9% | -
EBIT
-260.5%
Net
-254.3% | -154.0%
Free Cash Flow
-238.8%
Financial Health
Equity Ratio
-91.6%
Return on Equity
216.7%
ROCE
-945.5%
ROIC
-1,316.5%
Debt/Equity
0.0
More
EPS
$-1.2
FCF per Share
$-1.1
Short interest
1.6%
Employees
46
Rev per Employee
$430.0k
Show more

Is Carisma Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Carisma Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Carisma Therapeutics forecast:

6x Buy
75%
2x Hold
25%

Analyst Opinions

8 Analysts have issued a Carisma Therapeutics forecast:

Buy
75%
Hold
25%

Financial data from Carisma Therapeutics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
20 20
32% 32%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 21 21
19% 19%
103%
- Research and Development Expense 51 51
31% 31%
257%
-50 -50
39% 39%
-249%
- Depreciation and Amortization 2.32 2.32
39% 39%
12%
EBIT (Operating Income) EBIT -52 -52
39% 39%
-261%
Net Profit -51 -51
37% 37%
-254%

In millions USD.

Don't miss a Thing! We will send you all news about Carisma Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Carisma Therapeutics Stock News

Neutral
GlobeNewsWire
about one month ago
NEW YORK, July 05, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Neutral
PRNewsWire
about 2 months ago
NEW YORK , June 27, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Carisma Therapeutics Inc. (NASDAQ: CARM)'s  merger with OrthoCellix, Inc. Upon completion of the proposed transaction, existing Carisma shareholder...
Neutral
PRNewsWire
about 2 months ago
NEW YORK , June 23, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Couchbase, Inc. (NASDAQ: BASE)'s  sale to Haveli Investments for $24.50 per share in cash. If you are a Couchbase shareholder, click here to learn ...
More Carisma Therapeutics News

Company Profile

Carisma Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery and development of immunotherapies. It offers chimeric antigen receptor (CAR)-macrophages, a cell therapy platform focusing on the treatment of solid tumors. The company was founded by Michael Klichinsky and Saar Gill in 2016 and is headquartered in Philadelphia, PA.

Head office United States
CEO Steven Kelly
Employees 46
Founded 2016
Website sesenbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today